The effectiveness and limitations of regulatory warnings for the safe prescribing of citalopram
Author:
Publisher
Informa UK Limited
Subject
Health Policy,Pharmacology
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Toward Personalized Treatment of Depression: An Affordable Citalopram Test based on a Solid-Contact Potentiometric Electrode for at-Home Monitoring of the Antidepressant Dosage;ACS Sensors;2023-09-21
2. Effekt der Rote-Hand-Briefe zu Citalopram und Escitalopram auf Verordnungszahlen bei der stationären Behandlung von Angsterkrankungen;Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz;2022-09-28
3. Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data;European Archives of Psychiatry and Clinical Neuroscience;2022-02-25
4. Safer citalopram use in primary care: Can staff education and prescribing prompts improve adherence to national guidance? A closed loop clinical audit, service evaluation and quality improvement study;Journal of Family Medicine and Primary Care;2022
5. Effect of regulatory interventions on agomelatine use in Spain: A multiple intervention time‐series analysis in a nationwide electronic healthcare record database;Pharmacoepidemiology and Drug Safety;2021-11-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3